Altamira Therapeutics Statistics
Want to see CYTOF full AI Analyst Report?
Altamira Therapeutics (CYTOF) Stock Statistics & Valuation Metrics
Total Valuation
Altamira Therapeutics has a market cap or net worth of $404.65K. The enterprise value is $1.95M.
- Market Cap
- $404.65K
- Enterprise Value
- $1.95M
Share Statistics
Altamira Therapeutics has 5,715,472 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,715,472
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Altamira Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- 0
- Profits Per Employee
- -605.84K
- Employee Count
- 12
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Altamira Therapeutics had revenue of 0 and earned -7.27M in profits. Earnings per share was -14.81.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -5.92M
- Pretax Income
- -7.27M
- Net Income
- -7.27M
- EBITDA
- -1.35M
- Earnings Per Share (EPS)
- -14.81
Cash Flow
In the last 12 months, operating cash flow was -10.81M and capital expenditures 0, giving a free cash flow of -10.81M billion.
- Operating Cash Flow
- -10.81M
- Free Cash Flow
- -10.81M
- Free Cash Flow per Share
- ―
Stock Price Statistics
- Beta
- 1.88
- 52-Week Price Change
- -26.32%
- 50-Day Moving Average
- 0.08
- 200-Day Moving Average
- 0.08
- Relative Strength Index (RSI)
- 46.29
- Average Volume (3m)
- 7,190
Important Dates
Altamira Therapeutics upcoming earnings date is Apr 14, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 09, 2026
- Next Earnings Date
- Apr 14, 2027
- Ex-Dividend Date
- ―
Taxes
In the past 12 months, Altamira Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- ―
Balance Sheet
Altamira Therapeutics has $49.57K in cash and marketable securities with $3.47M in debt, giving a net cash position of -$3.42M billion.
- Cash & Marketable Securities
- $49.57K
- Total Debt
- $3.47M
- Net Cash
- -$3.42M
- Net Cash Per Share
- -$0.60
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Altamira Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 81.53%
Scores
- Smart Score
- ―
- AI Score
- 25
